로딩 중…
StockDiggingStockDigging

Hanmi Science Co.,Ltd

008930· KOSPI
₩29,650-1.50%
2026-06-19

Price Chart

Hanmi Science Co.,Ltd-34.40%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap2.03T KRW
Revenue1.38T KRW
Net Income135.55B KRW
Total Assets1.49T KRW
Net Assets1.00T KRW
Employees453
Value
P/E14.96x
P/B2.03x
PEG0.21x
P/S1.47x
EV/EBITDA47.45x
Profitability
ROE13.55%
ROA9.07%
Op. Margin10.53%
Revenue Growth6.49%
Earnings Growth72.95%
Financial Health
Debt Ratio49.48%
Total Debt186.72B KRW
Cash115.39B KRW
Current Ratio0.87x
Net Debt/EBITDA1.61x
Dividend
Div. Yield1.00%
Div. Growth0.00%
Performance
1Y Return-34.40%
1M Return-4.82%
From 52W High-46.58%
1Y MDD-45.18%
Trading
Volume102,522 shares
Foreign Own.1.97%
Per Share
EPS1,989 KRW
BPS14,761 KRW

Company Info

CEO 김재교
Employees 453
Founded 1973
HQ 경기도 화성시, KR

Hanmi Science, established in 1973, received approval for conversion to a holding company in 2011. In 2022, it merged with Hanmi Healthcare, adding a healthcare business division and transforming into an operating holding company. It generates profit through equity gains from subsidiaries, patent and trademark royalty income, healthcare business, and affiliate management, holding 8 subsidiaries including Hanmi Pharmaceutical. As an operating holding company, it is dedicated to discovering new growth engines, sharing new drug development risks, and establishing mid-to-long-term visions to lead the rapidly changing global healthcare market. Hanmi Science is headquartered in Hwaseong-si, Gyeonggi-do.